LRP8 and autoimmune polyendocrinopathy: To disrupt the core antigen-antibody interaction in APS, anti-β2GPI domain I monoclonal antibodies competitively block pathogenic aPL binding to β2GPI, preventing its engagement with cellular receptors like ApoER2 and subsequent complement activation (226, 227).